Current attitudes toward drug checking services and a comparison of expected with actual drugs present in street drug samples collected from opioid users.
Drug checking services
Fentanyl
Harm reduction
Opioid overdose-related fatalities
Substance use
Syringe program services
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
14
11
2022
accepted:
03
07
2023
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
The opioid epidemic continues to be associated with high numbers of fatalities in the USA and other countries, driven mainly by the inclusion of potent synthetic opioids in street drugs. Drug checking by means of various technologies is being increasingly implemented as a harm reduction strategy to inform users about constituent drugs in their street samples. We assessed how valued drug checking services (DCS) would be for opioid street drug users given the ubiquity of fentanyl and related analogs in the drug supply, the information they would most value from drug checking, and compared expected versus actual constituent drugs in collected samples. A convenience sample of opioid street drug users (N = 118) was recruited from two syringe service exchange programs in Chicago between 2021 and 2022. We administered brief surveys asking about overdose history, whether fentanyl was their preferred opioid, and interest in DCS. We also collected drug samples and asked participants what drug(s) they expected were in the sample. Provided samples were analyzed using LC-MS technology and the results compared to their expected drugs. Participants reported an average of 4.4 lifetime overdoses (SD = 4.8, range = 0-20) and 1.1 (SD = 1.8, range = 0-10) past-year overdoses. A majority (92.1%) believed they had recently used drugs containing fentanyl whether intentionally or unintentionally. Opinions about the desirability of fentanyl were mixed with 56.1% indicating they did not and 38.0% indicating they did prefer fentanyl over other opioids, mainly heroin. Attitudes toward DCS indicated a general but not uniform receptiveness with a majority indicating interest in DCS though sizeable minorities believed DCS was "too much trouble" (25.2%) or there was "no point" in testing (35.4%). Participants were especially inaccurate identifying common cutting agents and potentiating drugs such as diphenhydramine in their samples (sensitivity = .17). Results affirmed street drug users remain interested in using DCS to monitor their drugs and such services should be more widely available. Advanced checking technologies that provide information on the relative quantities and the different drugs present in a given sample available at point-of-care, would be most valuable but remain challenging to implement.
Sections du résumé
BACKGROUND
BACKGROUND
The opioid epidemic continues to be associated with high numbers of fatalities in the USA and other countries, driven mainly by the inclusion of potent synthetic opioids in street drugs. Drug checking by means of various technologies is being increasingly implemented as a harm reduction strategy to inform users about constituent drugs in their street samples. We assessed how valued drug checking services (DCS) would be for opioid street drug users given the ubiquity of fentanyl and related analogs in the drug supply, the information they would most value from drug checking, and compared expected versus actual constituent drugs in collected samples.
METHODS
METHODS
A convenience sample of opioid street drug users (N = 118) was recruited from two syringe service exchange programs in Chicago between 2021 and 2022. We administered brief surveys asking about overdose history, whether fentanyl was their preferred opioid, and interest in DCS. We also collected drug samples and asked participants what drug(s) they expected were in the sample. Provided samples were analyzed using LC-MS technology and the results compared to their expected drugs.
RESULTS
RESULTS
Participants reported an average of 4.4 lifetime overdoses (SD = 4.8, range = 0-20) and 1.1 (SD = 1.8, range = 0-10) past-year overdoses. A majority (92.1%) believed they had recently used drugs containing fentanyl whether intentionally or unintentionally. Opinions about the desirability of fentanyl were mixed with 56.1% indicating they did not and 38.0% indicating they did prefer fentanyl over other opioids, mainly heroin. Attitudes toward DCS indicated a general but not uniform receptiveness with a majority indicating interest in DCS though sizeable minorities believed DCS was "too much trouble" (25.2%) or there was "no point" in testing (35.4%). Participants were especially inaccurate identifying common cutting agents and potentiating drugs such as diphenhydramine in their samples (sensitivity = .17).
CONCLUSIONS
CONCLUSIONS
Results affirmed street drug users remain interested in using DCS to monitor their drugs and such services should be more widely available. Advanced checking technologies that provide information on the relative quantities and the different drugs present in a given sample available at point-of-care, would be most valuable but remain challenging to implement.
Identifiants
pubmed: 37420196
doi: 10.1186/s12954-023-00821-x
pii: 10.1186/s12954-023-00821-x
pmc: PMC10327398
doi:
Substances chimiques
Analgesics, Opioid
0
Illicit Drugs
0
Fentanyl
UF599785JZ
Heroin
70D95007SX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002003
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR002003
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Forensic Sci. 2021 Mar;66(2):664-676
pubmed: 33201526
Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S81-S85
pubmed: 35476024
Drug Alcohol Depend. 2021 Jan 1;218:108300
pubmed: 33127185
J Community Health. 2021 Apr;46(2):349-357
pubmed: 32997253
Int J Drug Policy. 2018 Dec;62:59-66
pubmed: 30359874
JAMA Netw Open. 2019 Apr 5;2(4):e192851
pubmed: 31026029
J Forensic Sci. 2020 Jul;65(4):1289-1297
pubmed: 32227600
Forensic Chem. 2023 May;33:
pubmed: 36910306
Drug Alcohol Depend. 2022 Jun 1;235:109427
pubmed: 35405459
Drug Alcohol Rev. 2020 Jan;39(1):98-102
pubmed: 31746056
Drug Test Anal. 2021 Apr;13(4):734-746
pubmed: 33646611
Subst Abus. 2020;41(4):468-474
pubmed: 32213045
Int J Drug Policy. 2019 Jun;68:46-53
pubmed: 30991301
Epidemiol Rev. 2020 Jan 31;42(1):134-153
pubmed: 32242239
Drug Alcohol Depend. 2022 May 1;234:109425
pubmed: 35344879
Epidemiol Rev. 2020 Jan 31;42(1):154-166
pubmed: 33511987
Drug Alcohol Depend. 2019 Jan 1;194:527-532
pubmed: 30551090
Int J Drug Policy. 2020 Mar;77:102661
pubmed: 31951925
Harm Reduct J. 2021 Jun 27;18(1):66
pubmed: 34176497
Ther Drug Monit. 2021 Apr 1;43(2):221-228
pubmed: 33298746
Am J Epidemiol. 2022 Jan 24;191(2):248-252
pubmed: 34528056
J Anal Toxicol. 2021 Jul 08;:
pubmed: 34233349
Drug Alcohol Depend. 2021 Nov 1;228:108976
pubmed: 34536717
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1189-1197
pubmed: 32881854
Drug Alcohol Depend. 2020 Jul 1;212:108006
pubmed: 32438280
Subst Abus. 2021;42(4):775-779
pubmed: 33617730
Drug Alcohol Depend. 2021 Jul 1;224:108722
pubmed: 33932743
Harm Reduct J. 2022 Feb 4;19(1):9
pubmed: 35120531
Harm Reduct J. 2019 Jan 8;16(1):3
pubmed: 30621699
Addiction. 2022 Oct;117(10):2745-2749
pubmed: 35543081
Int J Drug Policy. 2019 Sep;71:125-132
pubmed: 31336258
Drug Alcohol Depend. 2018 Sep 1;190:242-245
pubmed: 30064061
JAMA Netw Open. 2021 Feb 1;4(2):e2036687
pubmed: 33576816
Drug Alcohol Depend. 2021 Jan 1;218:108416
pubmed: 33278761
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1740-1746
pubmed: 34914673
Harm Reduct J. 2022 Jan 11;19(1):3
pubmed: 35012557
Int J Drug Policy. 2018 Nov;61:52-58
pubmed: 30344005
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
J Psychoactive Drugs. 2023 Jan-Mar;55(1):85-93
pubmed: 35060837
J Anal Toxicol. 2021 Jan 21;44(9):937-946
pubmed: 32744605
Int J Drug Policy. 2022 May;103:103643
pubmed: 35255392
Addiction. 2022 Mar;117(3):532-544
pubmed: 34729849
Drug Alcohol Rev. 2022 Feb;41(2):410-418
pubmed: 34347332
Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350
pubmed: 33965972
Drug Alcohol Depend. 2022 May 1;234:109398
pubmed: 35370014
J Subst Abuse Treat. 2022 Sep;140:108790
pubmed: 35577663
Curr Pain Headache Rep. 2018 Apr 3;22(4):31
pubmed: 29616344